scholarly journals The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome

2016 ◽  
Vol 91 (10) ◽  
pp. E436-E441 ◽  
Author(s):  
Jacob R. Bledsoe ◽  
Robert A. Redd ◽  
Robert P. Hasserjian ◽  
Jacob D. Soumerai ◽  
Ha T. Nishino ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Biomarkers ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

2006 ◽  
Vol 24 (6) ◽  
pp. 995-1007 ◽  
Author(s):  
Izidore S. Lossos ◽  
Daniel Morgensztern
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Genetic Alterations ◽  
Response To Therapy ◽  
Prognostic Biomarkers ◽  
Diagnostic Tools ◽  
Routine Practice ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Although it represents a curable disease, less than half of the patients are cured with conventional chemotherapy. The highly variable outcome reflects a heterogeneous group of tumors, with different genetic abnormalities and response to therapy. The International Prognostic Index (IPI) is useful in predicting the outcome of DLBCL patients. However, patients with identical IPI still exhibit marked variability in survival, suggesting the presence of significant residual heterogeneity within each IPI category. The discovery of specific genetic alterations and the assessment of protein expression led to the identification of multiple novel single molecular markers capable of predicting the outcome of DLBCL patients independently of clinical variables. The recent application of DNA microarrays and tissue array technologies allowed a better understanding of the biology of lymphoma and the development of novel diagnostic tools capable of improving the current models for outcome prediction. However, much confusion exists in the literature regarding the importance of different prognostic biomarkers and their applicability in routine practice. This review summarizes the recent advances in our understanding of prognostic biomarkers in DLBCL and discusses whether this is the right time for biomarkers-guided risk-adjusted therapy.

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

2016 ◽  
Vol 35 (4) ◽  
pp. 480-486 ◽  
Author(s):  
Jung Yong Hong ◽  
Kyung Ju Ryu ◽  
Ji Yean Lee ◽  
Chaehwa Park ◽  
Young Hyeh Ko ◽  
...  
Keyword(s):  
Serum Level ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Biomarkers ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi

2020 ◽  
Vol 33 (8) ◽  
pp. 1482-1491
Author(s):  
Yuri Fedoriw ◽  
Sara Selitsky ◽  
Nathan D. Montgomery ◽  
Sviatoslav M. Kendall ◽  
Kristy L. Richards ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Biomarkers ◽  
Transcriptional Profiles ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers

PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0186983 ◽  
Author(s):  
Mette Ølgod Pedersen ◽  
Anne Ortved Gang ◽  
Peter Brown ◽  
Michael Pedersen ◽  
Helle Knudsen ◽  
...  
Keyword(s):  
High Risk ◽  
B Cell ◽  
Real World ◽  
Cell Lymphoma ◽  
Young Patients ◽  
B Cell Lymphoma ◽  
Prognostic Biomarkers ◽  
Real World Data ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document